lutetium-lu-177-dotatate and Peritoneal-Diseases

lutetium-lu-177-dotatate has been researched along with Peritoneal-Diseases* in 1 studies

Other Studies

1 other study(ies) available for lutetium-lu-177-dotatate and Peritoneal-Diseases

Article	Year
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021, Volume: 62, Issue:1 Although radiation-induced mesenteritis or peritonitis can potentially exacerbate the risk of bowel obstruction, there are no data in the literature on the incidence of intestinal obstruction related to peptide receptor radionuclide therapy. Topics: Female; Humans; Intestinal Obstruction; Male; Mesentery; Middle Aged; Octreotide; Organometallic Compounds; Peritoneal Diseases; Receptors, Peptide; Risk	2021

Article

Year

Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021, Volume: 62, Issue:1

Although radiation-induced mesenteritis or peritonitis can potentially exacerbate the risk of bowel obstruction, there are no data in the literature on the incidence of intestinal obstruction related to peptide receptor radionuclide therapy.

Topics: Female; Humans; Intestinal Obstruction; Male; Mesentery; Middle Aged; Octreotide; Organometallic Compounds; Peritoneal Diseases; Receptors, Peptide; Risk

2021